Eisai Receives "IR Grand Prix Award"

Nov 14, 2018 13:30 JST

Source: Eisai

TOKYO, Nov 14, 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). This marks the second time that Eisai has received the IR Grand Prix Award following 2006. Including the receipt of Best IR Awards in 2004, 2005, 2009 and 2012, this is the 6th time Eisai has received an IR Award, and Eisai is the first pharmaceutical company to receive two IR Grand Prix Awards.

The IR Award (Committee Chairman: Tetsuo Kitagawa, Professor of International Management, Aoyama Gakuin University Graduate School) is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities, and this year marks the 23rd year since the start of the IR Awards. 299 companies applied for the IR Award 2018, and after surveys and screenings by select committee members, Eisai was the sole company selected for the IR Grand Prix Award this year.

The reasons for Eisai's selection are as follows:
"Eisai is proactively disclosing information and constantly raising the level of disclosure. For many years, top management has been engaged in dialogue with investors, candidly discussing the company's longer-term vision and management issues. Eisai's CFO and IR Department have been enhancing the presentation of balance sheet management and disclosure of non-financial information ahead of other companies. In terms of ESG-related efforts, Eisai not only discloses information but also holds meetings with presentations by outside directors and meetings to explain its integrated report. The company's timeliness and fairness in disclosure is highly regarded, evidenced by its timely disclosure of information that may affect operating performance and prompt holding of briefings on such matters."

Furthermore, in celebration of the 25th year since the establishment of the JIRA, as part of the "JIRA 25th Anniversary Commemorative Award" which seeks to specially recognize companies which have continued IR activities over the long term and have produced outstanding achievements in appropriate information disclosure and constructive dialogue with investors and shareholders, Eisai was selected as both a "Company with Greatest Improvement in IR" and as a "Company with Best Continual Efforts in IR." For further details, please visit the JIRA website: https://www.jira.or.jp/english/.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

May 21 2026 23:23 JST

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

April 21 2026 19:52 JST

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

March 27 2026 19:14 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27 2026 17:19 JST

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

March 23 2026 10:19 JST

Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)

March 19 2026 09:54 JST

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

March 17 2026 18:49 JST

Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration

March 12 2026 16:21 JST

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

March 11 2026 11:07 JST

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

March 02 2026 08:49 JST

More Press release >>

Latest Press Release

Wheelchair Racer Catherine Debrunner Breaks Her Own World Record, Sets New Mark in the 200 Meters (T53) at the World Para Athletics Grand Prix (Switzerland)
May 27, 2026 22:45 JST

Fujitsu signs strategic partnership with Anthropic
May 27, 2026 22:03 JST

Fujitsu to accelerate AI transformation in Japan's enterprise sector through collaboration with OpenAI
May 27, 2026 21:18 JST

Hitachi Energy and Volvo Construction Equipment announce collaboration to accelerate zero-emission construction sites
May 27, 2026 20:19 JST

NEC and New York University Evaluate Economic Impact of Flood Protection Project Around the Island of Manhattan
May 27, 2026 12:03 JST

Fujitsu provides core business system for real-time information management of all Japan Maritime Self-Defense Force supplies
May 26, 2026 19:20 JST

Fujitsu's groundbreaking computing technology for accelerating scientific computing wins the Prime Minister's Prize in Japan
May 26, 2026 13:50 JST

NTT, Kubota and NTT DOCOMO Demonstrate Communication Technologies Enabling Remote Operation of Robotic Agricultural Machinery in Mountainous Areas
May 26, 2026 13:30 JST

Successful Demonstration of Stable, High-Capacity mmWave Communications for Multiple High-Speed Vehicles for the 6G Era
May 25, 2026 14:58 JST

Fujitsu develops self-evolving multi-AI agent technology that learns and adapts to business operations
May 25, 2026 14:13 JST

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 00:23 JST

Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 00:16 JST

Fujitsu supports the Panasonic Group in accelerating its sustainability management through the implementation of a CFP calculation solution
May 21, 2026 13:57 JST

Sharp Launches Poketomo Conversational AI Character in Taiwan
May 21, 2026 13:55 JST

Hitachi Energy's HMAX Energy service solutions strengthen long-term reliability for Akaysha Energy's Ulinda Park BESS
May 21, 2026 13:40 JST

Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
May 20, 2026 17:00 JST

Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
May 20, 2026 13:50 JST

Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
May 19, 2026 23:09 JST

SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST

Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST

More Latest Release >>